Clinical Trials on PD-L1
Total 208 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Baodong QinUnknown
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Maastricht Radiation OncologyCompletedProstate Cancer | PD-L1Netherlands
-
Sarah GoldbergMirati Therapeutics Inc.TerminatedLung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | SitravatinibUnited States
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; Gilead SciencesRecruitingBreast Cancer | Triple Negative Breast Cancer | PD-L1 NegativeUnited States
-
Kidney Cancer Research BureauRecruitingMetastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene AmplificationUnited States
-
Consorzio OncotechActive, not recruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | PD-L1 Gene MutationItaly
-
Peking University Cancer Hospital & InstituteRecruitingMelanoma | Lung Cancer | PD-L1 | PET/CTChina
-
Shirish M GadgeelAstraZeneca; Henry Ford Health SystemWithdrawnLung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating MutationUnited States
-
Shanghai Cancer Hospital, ChinaUnknownLung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRTChina
-
Poitiers University HospitalActive, not recruitingNon Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CTFrance
-
University of Colorado, DenverCancer League of ColoradoWithdrawnMetastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene MutationUnited States
-
Institute of Oncology LjubljanaUniversity of Ljubljana; Military Medical Academy, Belgrade, SerbiaRecruitingMetastatic Melanoma | Immune Checkpoints Inhibitors | Gastrointestinal Microbiome (Bacterial and Viral) | Exosomal mRNA Expression of PD-L1 and IFNγSlovenia
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Xiaohua ZhuRecruitingNSCLC Stage IV | PD-L1 Gene AmplificationChina
-
The First Hospital of Jilin UniversityRecruitingPD-L1 Positive Locally Advanced Patients With Resectable Gastric CancerChina
-
Xiaorong DongUnknown
-
Cairo UniversityAbdelhamid, Bassant Mohamed, M.D.; Mohamed, Ahmed A., M.D.; Hala Mostafa Gomaa; Mohamed saeid AliCompletedUltrasound Guided L1,L2 Paravertebral BlockEgypt
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Samsung Medical CenterUnknown
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Shirish GadgeelMerck Sharp & Dohme LLCWithdrawnNon Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma
-
The Second Affiliated Hospital of Harbin Medical...UnknownContract Management PD
-
Sun Yat-sen UniversityRecruitingInduction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | EnvafolimabChina
-
Istituto Scientifico Romagnolo per lo Studio e...RecruitingProgressive Disease | Mesothelioma, Malignant | Advanced Cancer | PD-L1 NegativeItaly
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedHealthy Subjects | PK/PDChina
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Hadassah Medical OrganizationRecruitingAminoglycoside Dosing Based on PK/PD CharacteristicsIsrael
-
iOMEDICO AGRoche Pharma AGCompletedExtensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBCGermany
-
AstraZenecaPRA Health SciencesCompletedRecurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and NeckUnited States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
-
AstraZenecaCompletedRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNUnited States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
Peking UniversityNot yet recruitingGastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
-
Sharp HealthCareNo longer availablePrior Treatment With PD-0325901 With Ongoing Clinical ResponseUnited States